FDA Warning Letter To Empower Pharmacy And What It Means For 503A Compounding Pharmacies

The U.S. Food and Drug Administration’s September 18, 2026 warning letter to Empower Pharmacy⁠, published on September 22, 2026, provides important insight into FDA’s scrutiny of compounded semaglutide and tirzepatide. The letter addresses whether certain formulations qualified for exemptions under Section 503A of the Federal Food, Drug and Cosmetic Act, with particular attention to prescriber determinations of “significant difference,” prescription documentation, production volume and third-party prescribing platforms.

For 503A pharmacies, the letter warrants a careful review of the clinical determinations and operational practices supporting their compounding activities. Although it does not establish a blanket prohibition on compounded GLP-1 medications, it demonstrates that FDA may examine whether a pharmacy’s records substantiate individualized prescribing decisions, particularly when the same formulations and justifications appear across substantial numbers of prescriptions.

The letter also presents a separate set of concerns involving sterile compounding, supporting records and the effectiveness of corrective actions. The practical response should be serious and deliberate, but not alarmist: pharmacies should evaluate whether their records and operations support the legal basis on which they compound and dispense each affected product.

What FDA Alleged in the Empower Pharmacy Warning Letter

Warning Letter No. 738238 followed FDA’s November 3–14, 2025 inspection of Empower’s 503A pharmacy in Houston, Texas. FDA acknowledged several responses submitted after the inspection but concluded that certain compounded products failed to satisfy Section 503A and identified additional concerns involving sterile compounding practices.

FDA specifically identified tirzepatide/niacinamide and semaglutide/cyanocobalamin formulations that it ultimately determined to be essentially copies of commercially available drugs. According to the letter, investigators collected:

• Prescriptions lacking a prescriber determination of significant difference;
• Prescriptions containing significant-difference determinations repeated verbatim across numerous records, which FDA suggested may have been pre-generated for prescriber selection; and
• Production records showing regular compounding and substantial dispensing activity.

Although FDA relied on production and dispensing volumes to support its position, the numerical quantities are redacted in the public letter. FDA nevertheless stated that the volume suggested that the differences between the compounded products and the FDA-approved products were “pretextual.”

These allegations should be understood as FDA’s enforcement position based on the records described in the letter. The warning letter provides an opportunity for response and does not constitute a judicial determination resolving disputed facts or legal interpretations.

Understanding the Section 503A Significant-Difference Standard

Section 503A provides qualifying compounded drugs with exemptions from FDA premarket approval, labeling with adequate directions for use and current good manufacturing practice requirements. These exemptions depend on satisfaction of statutory conditions, including restrictions against regularly compounding or compounding in inordinate amounts, drugs that are essentially copies of commercially available products.

Section 503A(b)(2)⁠ excludes a compounded drug from the essentially-copy category when a change made for an identified individual patient produces a significant difference for that patient, as determined by the prescribing practitioner. Accordingly, the analysis involves both the formulation change and the prescriber’s determination concerning the particular patient. Adding niacinamide, vitamin B12 or another ingredient does not, standing alone, establish that the resulting product satisfies this provision.

For pharmacies relying on significant-difference determinations, the practical concern is whether their records connect the prescribed change to its significance for the patient receiving the medication. A prescription identifying the patient and a compounded formulation may not adequately document that determination when it provides no explanation of the relevant change or its patient-specific significance.

Why Prescriber Statements and Technology Platforms Matter

A particularly important aspect of the letter is FDA’s scrutiny of how significant-difference statements were generated. FDA questioned whether language repeated across numerous prescriptions reflected individualized clinical judgment or statements prepared in advance for prescribers to select. The agency also identified third-party technology platforms offering preselected menu options as potentially undermining the individualized nature of those determinations.

For pharmacies working with telehealth providers and prescribing platforms, this concern extends beyond whether a prescription includes an attestation. Pharmacies should understand how the prescriber evaluates the patient, how the significant-difference statement enters the prescription and whether the documentation accurately reflects the prescriber’s determination. Replacing a checkbox with a free-text field will not, standing alone, necessarily address an underlying absence of individualized assessment.

At the same time, the letter should not be interpreted as categorically prohibiting standardized forms or requiring different wording for every patient. FDA’s guidance, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A⁠, does not prescribe a particular documentation format. It explains that FDA generally does not intend to question a prescriber’s documented determination that a change produces a significant difference for an identified patient. The relevant question is whether the documentation reflects the patient’s circumstances and the prescriber’s judgment, rather than merely completing a required field.

When a prescription is unclear, the guidance allows the compounder to contact the prescriber and document the confirmed determination, including the relevant change, the significant difference it produces for the patient and the date of the conversation. Pharmacies should incorporate appropriate clarification procedures into their workflows while preserving original records and accurately documenting subsequent communications.

How Prescription Volume Affects the Analysis

FDA relied on production and dispensing volumes to support its concern that the asserted differences were pretextual. This reasoning deserves attention from pharmacies participating in programs where large numbers of patients receive the same compounded formulation accompanied by the same justification.

Nevertheless, high volume does not automatically eliminate the statutory significant-difference provision. FDA’s guidance recognizes that the restriction against regular or inordinate compounding is not implicated when the compounded product is not essentially a copy. Pharmacies should therefore evaluate volume alongside the underlying prescriptions and clinical determinations, without assuming that either high volume establishes a violation or a signed attestation conclusively establishes compliance.

Volume remains an important compliance signal. Sustained production of the same formulation, paired with identical patient rationales, can invite scrutiny concerning whether the asserted differences are genuine and individualized. Pharmacies should be prepared to explain both the clinical basis for the prescriptions and the aggregate pattern reflected in their production records.

The Consequences of Losing Section 503A Eligibility

FDA did not characterize the identified issues as documentation deficiencies alone. The agency asserted that products failing to satisfy Section 503A lost their statutory exemptions and were therefore subject to federal requirements governing drug approval, adequate directions for use and CGMP.

FDA consequently characterized the products as unapproved new drugs and misbranded drugs. It also asserted that the manufacture of those allegedly ineligible products was subject to CGMP requirements and cited several alleged CGMP violations.

It is important to understand the implications of FDA determinations that products that were previously prepared and dispensed did not qualify for exemptions under 503(a). In this instance, the failure to satisfy one condition of Section 503A changed the federal legal framework applicable to the product and led to additional allegations involving approval, labeling, manufacturing practices and prohibited acts under the FD&C Act.

Sterile Compounding and Documentation Remain Separate Concerns

The warning letter also alleged inadequate smoke studies under dynamic conditions and media fills that did not reflect the most challenging operating conditions. In reviewing corrective actions, FDA identified insufficient supporting documentation, discrepancies in vial counts, missing or unexplained entries, undefined “N/A” designations and concerns about transcribing results without a clear audit trail. These findings illustrate why a favorable validation summary may be insufficient when the underlying records do not support its conclusions.

FDA also cited alleged deficiencies involving equipment maintenance, procedures intended to prevent microbiological contamination, quality-unit oversight, environmental monitoring and written production and process controls.

The distinction between Section 503A eligibility and insanitary conditions is particularly important for pharmacy operators. Qualifying Section 503A products remain exempt from CGMP requirements, but the federal prohibition against insanitary conditions applies regardless of that eligibility. Separately, FDA asserted CGMP violations for the products it considered ineligible for Section 503A exemptions. A pharmacy, therefore, depending on its circumstances, may not be able to address the full scope of the letter merely by modifying its GLP-1 prescription-documentation process.

What 503A Pharmacies Should Review Now

1. Conduct a targeted review of significant-difference determinations

Pharmacies should review a representative sample of semaglutide and tirzepatide prescriptions, corresponding formulations and related prescriber communications. Where a significant difference is the basis for treating a formulation as outside the essentially-copy restriction, the records should identify the relevant change and its significance for the particular patient.

The review should test the actual patient records—not simply policies, template language or prescription forms. Unclear or unsupported statements should prompt appropriate clarification before the pharmacy relies on them.

2. Identify repeated rationales and prescribing outliers

Repeated language is not necessarily proof that a determination is invalid. Similar clinical circumstances can recur, and structured documentation can improve completeness. Extensive verbatim repetition across a high volume of prescriptions, however, creates a foreseeable enforcement risk.

Pharmacies should consider data analytics or targeted sampling to identify commonly repeated rationales, unusually high prescribing volumes and patterns concentrated among particular prescribers, formulations or telehealth partners. Outliers should receive meaningful clinical and compliance review.

3. Audit the actual telehealth and prescribing workflow

Pharmacies should examine relationships with telehealth providers and technology vendors, including who develops prescribing language, whether selections are pre-populated or pre-selected, whether prescribers can provide patient-specific explanations and what information is retained in the record.

Contract language requiring independent clinical judgment is helpful, but it will not cure a workflow that channels prescribers toward a predetermined answer. Agreements should support access to necessary documentation, appropriate auditing, record retention, timely communication with prescribers and corrective action when problematic patterns are identified. A vendor’s representation that its platform is compliant does not resolve deficiencies in the actual prescribing process.

4. Monitor aggregate production and dispensing patterns

Pharmacies should establish reporting that allows compliance personnel to compare formulations, concentrations, added ingredients, prescribers, stated clinical rationales and monthly dispensing volume. A sharp increase or prolonged high-volume pattern should trigger review before it becomes the basis for an inspectional finding.

The addition of niacinamide, cyanocobalamin or another ingredient—or a change in concentration or vial size—should not be treated as a categorical safe harbor. The pharmacy should be able to connect the change to the needs of the identified patient and the prescriber’s significant-difference determination.

5. Confirm that marketing and operations tell the same story

Prescription records, intake processes, prescriber education, telehealth workflows and marketing materials should be evaluated together. A patient-specific statement in a prescription may receive less weight if surrounding evidence suggests that the formulation was promoted broadly as a standardized substitute for an approved product.

Pharmacies should review public-facing and partner-facing materials for claims that could conflict with the individualized basis reflected in prescription records.

6. Reassess sterile-process validation and data integrity

Sterile compounders should confirm, among other things, that smoke studies reflect dynamic operating conditions and that media fills simulate the most challenging conditions actually encountered in production. Validation reports, investigations and corrective actions should be supported by complete and consistent underlying records.

Vial reconciliation, deviations, unexplained designations and data transcriptions should be documented through a reliable audit trail. If original results are corrected or transcribed, the reason, the responsible individual, the authorization, the date and the relationship to the original record should be clear. A technically sound corrective action may receive limited regulatory credit if the supporting submission does not allow FDA to evaluate it.

Identified gaps should be evaluated with counsel and appropriate quality personnel to determine whether clarification, operational changes, additional validation or a pause in affected activities is warranted. Where appropriate, management should consider an independent consultant with relevant sterile drug-manufacturing expertise—an action FDA specifically recommended in the Empower letter.

7. Maintain meaningful oversight of contractors

FDA reiterated that outsourcing a function does not outsource regulatory responsibility. Pharmacies using contract laboratories or other vendors should document their qualification process, define responsibilities in appropriate agreements, review deviations and out-of-specification results, monitor performance and retain access to the underlying records needed to evaluate compliance.

Protecting Lawful Compounding and Patient Access

The Empower warning letter underscores the importance of substantiating the patient-specific basis for compounded therapy while maintaining reliable compounding practices. It does not establish that all compounded semaglutide or tirzepatide products are prohibited, nor does it eliminate the statutory significant-difference pathway. It does show that FDA has not taken a public position showing that it intends to scrutinize whether claimed differences are genuine and patient-specific, particularly when the same formulation and justification appear repeatedly at scale.

Pharmacies should respond by examining their own operations and documentation, recognizing both FDA’s enforcement concerns and the statutory framework that continues to support qualifying individualized therapies. The compliance objective is to ensure that operational reality matches the patient-specific rationale reflected in the record—and that the pharmacy can demonstrate that alignment through contemporaneous, reliable evidence.